

Estimation of endotoxin level in nanocrystal dispersion of DK-I-56-1 intended for parenteral administration

Jelena Mitrović¹, Tanja Ilić¹, Ivan Jančić², Biljana Bufan², Miroslav Savić³, Snežana Savić¹

¹ Department of Pharmaceutical Technology and Cosmetology, University of Belgrade – Faculty of Pharmacy, Vojvode Stepe 450, 11000 Belgrade, Serbia

² Department of Microbiology and Immunology, University of Belgrade – Faculty of Pharmacy, Vojvode Stepe 450, 11000 Belgrade, Serbia

³ Department of Pharmacology, University of Belgrade – Faculty of Pharmacy, Vojvode Stepe 450, 11000 Belgrade, Serbia

Science Fund
of the Republic of Serbia




Introduction and Aim


Estimation of endotoxin level in parenteral formulations is a prerequisite for numerous in vitro tests in preclinical studies and for future clinical development. However, the Limulus amoebocyte lysate (LAL) test in formulations containing nanoparticles could often lead to misinterpretation of results (1, 2). Therefore, we tested if endotoxins could be detected in nanocrystal dispersions by the commercial gel clot assay kit

Methods

Nanocrystals of DK-I-56-1 (7-methoxy-2-(4-methoxy-d3-phenyl)-2,5-dihydro-3H-pyrazolo[4,3-c]quinolin-3-one) were prepared by wet-ball milling, lyophilized and reconstituted with water for injection prior experiment (3). Different dilutions of nanocrystal dispersion in LAL reagent water were prepared as well as positive and negative control.




Results



Particle size distribution

LAL test results

dilution	1:150	1:100	1:75	1:50	1:25
gel clot	-	-	+	+	+



Dilution 1:100



Dilution 1:75



Dilution 1:25

Conclusion

Despite difficulties to detect gel clots, they were visible in the sample at dilutions 1:75 and below. According to the protocol, the endotoxin limit was estimated to be 25.00 EU/ml, which corresponds to <12.50 EU/mg of DK-I-56-1. This value relates to the endotoxin limit for diazepam, with the similar dosing regimen as proposed for DK-I-56-1.

References

- 1 Mangini, M. et al. *Nanotoxicology* 2021, 15, 558–576.
- 2 Ilić, T. et al. *Pharmaceutics* 2023, 15(2), 443.
- 3 Mitrović, JR. et al. *Eur J Pharm Sci* 2023, 189, 106557

Acknowledgement

This research was supported by the Science Fund of the Republic of Serbia, grant No. 7749108, project Neuroimmune aspects of mood, anxiety and cognitive effects of leads/drug candidates acting at GABAA and/or sigma-2 receptors: In vitro/in vivo delineation by nano- and hiPSC-based platforms-NanoCellEmoCog.